Biomind Labs Inc.
BMND
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Net Income | 72.53% | 41.26% | 57.07% | 48.94% | 86.41% |
| Total Depreciation and Amortization | 0.00% | -73.17% | -54.17% | -100.00% | -80.70% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -1,780.00% | 6,368.75% | 150.00% | 37.19% | -103.25% |
| Change in Net Operating Assets | -126.26% | -56.67% | -104.90% | -214.30% | -104.37% |
| Cash from Operations | 18.49% | 84.62% | 54.87% | 36.96% | 77.06% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -75.60% | -51.16% | -67.81% | -- | -- |
| Total Debt Repaid | -- | -- | -- | 111.90% | 100.00% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -77.83% | -50.79% | -66.84% | 1,371.43% | 2,237.38% |
| Foreign Exchange rate Adjustments | 253.91% | -140.00% | 115.18% | 95.97% | -13.02% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -133.92% | -128.42% | 285.83% | 72.37% | 110.87% |